Drug Research
Shionogi and Hsiri to develop mycobacterial disease therapies
Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases, as well as tuberculosis (TB).
The agreement covers a technology that will complement the company’s previous...
Drug Research
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta T-cells to develop transformational immunotherapies, announced the formation of a spin-out company: Adaptate Biotherapeutics. While GammaDelta Therapeutics’ primary goal is to develop γδ T-cell based cell...
Drug Research
Insilico Medicine and ChemDiv form a strategic drug discovery service alliance
Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration combines the most advanced artificial intelligence (AI) techniques with a premium integrated drug discovery shared...
Drug Research
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients
Bayer AG and its development partner Janssen Research & Development, LLC announced that the U.S. FDA has approved rivaroxaban (Xarelto) for the prevention of venous thromboembolism (VTE), or blood clots, in acutely ill medical patients at risk for thromboembolic...
Drug Research
Arctoris Ltd Secures Seed Funding of £3.2 Million to Advance Novel Drug Discovery Platform Powered by Robotics
Arctoris Ltd, a fully automated drug discovery platform for virtual and traditional biotechnology companies, pharmaceutical corporations and academia, announced that it has successfully closed a seed funding round of £3.2 million to advance its novel drug discovery offering.
The funding...
Drug Research
Novel silica delivery system Nuvec (R) enters final pre-clinical development stage
N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company, has announced results fromthe company’s latest research study into its novel silica nanoparticle for cancer treatments and vaccines, Nuvec®. The work, which repeated and expanded on a previouspDNA OVA study,...
Drug Research
Sygnature Discovery moves US base to Kendall Square
Sygnature Discovery, the leading independent drug discovery and pre-clinical services company, has announced its US office has moved. The new office, at 245 First Street in Cambridge, MA, is near Kendall Square, the heart of the Cambridge–Boston biotech hub.
It’s...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
